Entrectinib Effective across NTRK Fusion-Positive Cancers.
Entrectinib may be an effective therapy for patients with NTRK fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to the drug, with a similar response rate in patients whose cancer had spread to the brain.